Fusion Pharmaceuticals Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation expense
Depreciation and amortization expense
Non-cash rent expense
Non-cash lease expense
Change in fair value of preferred share tranche right liability
Change in fair value of preferred share warrant liability
Non-cash interest expense
Accretion of discounts on investments, net
Deferred tax provision (benefit)
Foreign exchange loss
Common shares issued to acquire in-process research & development
Other

Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Operating lease right-of-use assets
Other non-current assets
Accounts payable
Accrued expenses and other current liabilities
Deferred revenue
Income taxes payable
Operating lease liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of investments
Maturities of investments
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of Class B convertible preferred shares and Class B preferred share tranche right, net of issuance costs
Proceeds from issuance of Class B preferred exchangeable shares of Fusion Pharmaceuticals (Ireland) Limited and Class B preferred share tranche right, net of issuance costs
Proceeds from the issuance of common shares upon closing of initial public offering, net of underwriter fees
Proceeds from issuance of debt
Proceeds from issuance of common shares from private placements
Proceeds from issuance of common shares from at-the-market offering, net of issuance costs
Payment of offering costs
Proceeds from issuance of common shares upon exercise of stock options
Proceeds from issuance of common shares upon exercise of stock options and ESPP
Net cash provided by financing activities

Net increase in cash, cash equivalents and restricted cash
Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for income taxes
Cash paid for interest
Right-of-use assets obtained in exchange for new operating lease liabilities
Increase in right-of-use assets and operating lease liabilities from operating lease modifications
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses
Issuance of warrants to purchase Class B preferred shares and Class B preferred exchangeable shares as a non-cash dividend to preferred shareholders

Comments